HairClone is a startup biotechnology company focused on developing personalised treatments using a patient’s own cultured hair cells to reverse hair loss. Step one of this process which involves looking to create what aims to be the world's first follicle banking service, to be launched in 2019.

 

HairClone

INVESTMENT RAISED24.6%
Maturity

Prototyping, preclinical

Sector Biotechnology
Market

Hair loss (androgenic alopecia)

Goal

£300,000


This is the investment proposal of HairClone

Valuation

£3,000,000

% Offered

9.09%

Minimum investment: £100
Target Exit Type: IPO or Trade Sale
Drag Along
Tag Along
Tax Breaks
Why Capital Cell endorses this company?

HairClone is aiming to enter a very large market worth $4bn for surgical hair restoration alonesource. With their rejuvenation arm of the business, they hope to grow this market by attracting a whole new set of customers.
Furthermore, early biobanking of hair cells increases the likelihood of future hair rejuvenation/regeneration and could, therefore, build continuous revenues for the business.

Investment risk

HairClone’s 2nd therapy is still in a testing phase and currently, there are no supporting figures for the success rate of the treatments. Other risks associated with an investment of this type can be found here.

More information
Previous Next

What our experts say

The final rating*

Team
85%
Science
73%
Innovation
81%
Business
88%
Pre-money Valuation

£3,000,000

Offered equity

9.09%

Minimum investment

£100

*The BioExpert Network is an independent and exclusive network of industry experts in the sectors of life science and investment. Only proposals which receive the most positive responses, in terms of novel concepts, scientific validity and financial perspective successfully progress to funding campaign stage on the Capital Cell online platform. The opinions of our BioExpert Network cannot be relied upon as a guide to the likely successes of the company. Investors need to conduct their own due diligence and analysis before deciding whether to invest in a Capital Cell listed business.
Making hair loss history
HairClone 70 Quay Street Manchester M33EJ

HairClone is developing two personalised therapies to treat the most common cause of hair loss in men and women (androgenic alopecia). HairClone's lead treatment aims to rejuvenate thinning hairs for patients when they first notice hair loss, their second treatment aims to regenerate brand new hair follicles for patients with extensive hair loss. These treatments, if successful, would dramatically revolutionise the market by filling the unmet needs of women with female pattern baldness, men for whom it is too early in the balding process for hair transplantation to be recommended and patients who need greater coverage than can be achieved by transplantation. In 2019 HairClone aims to launch the world's first hair follicle banking service which will allow patients to store a small number of hair follicles for future expansion. They have an expanding clinical partner network of leading hair transplant surgeons around the world who are providing non-dilutive co-funding and a deep clinical know-how and expertise, linking them to patients for both banking and later treatment.

The team

The team have been founders, CEOs and Directors at multiple public and private Biotechs in the US, EU and UK. They have developed cell-based products that have treated approximately one million people and the Medical Directors have performed over 7,000 hair transplants between them. HairClone's team has extensive clinical and regulatory experience and have been involved in the design and operation of over 20 clinical trials around the world including the world's first trial using cultured hair follicle cells.

Executive Team

Paul Kemp PhD
CEO

Paul is a founding Director of HairClone. He has over 25 years’ experience in the development and commercialisation of Regenerative Medicine and Cell Therapy products. He has developed commercialised cell therapy treatments and grown companies from founding to flotation. He has raised over £25M from International VC funds and previously he has held Executive Board level positions in both public and private Companies in the UK and US (Organogenesis, Intercytex).

 
Vincent Ronford, PhD
CSO

Vincent has more than 28 years of experience of applied research and product development in the fields of regenerative medicine, wound healing and cosmetics. He has worked in companies in Europe, United States and Asia (Organogenesis, L’Oreal, Smith and Nephew). He is currently Scientific Director of HairClone (UK) and Chief Innovation Officer at Cutiss AG (Switzerland).

 
Dr Bessam Farjo MB, ChB, BAO, LRCP & SI
Medical Director

Qualified from the Royal College of Surgeons in Ireland and co-founded the Farjo Hair Institute in 1993 exclusively offering hair transplant surgery and hair restoration medicine. Dr Farjo is a Past President of both British Association of Hair Restoration Surgery and International Society of Hair Restoration Surgery. He is a diplomate of American Board of Hair Restoration Surgery, Past Medical Director of Institute of Trichologists and member of European Hair Research Society.

 
Dr Nilofer Farjo, MB, ChB
Medical Director

Nilofer Farjo has been performing hair transplants for 25 years and is recognised for her educational and leadership contributions at international congresses and meetings. She also has been acknowledged by her peers for outstanding achievement in basic science or clinically-related research in hair pathophysiology or anatomy as it relates to hair restoration for which she was awarded the ISHRS Platinum Award in 2012. Nilofer currently works on hair biology research with six UK Universities.

 
Eric Halioua MS, MBA
Head of Business and Corporate Development

Eric is a serial entrepreneur who has raised nearly €90 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-founder of four biotechnology companies called Myosix, Murigenetics, HairClone and Digital Orthopaedics. Eric is also Board member of the biotechnology companies Bioxodes, VitriCell and Innobiochips. He was principal of the life sciences practice of Arthur D. Little in Paris and Boston.